TABLE OF CONTENTS
1 INTRODUCTION 9
1.1 OBJECTIVES OF THE STUDY 9
1.2 MARKET DEFINITION 9
1.3 OVERVIEW OF TURKEY RX DRY EYE MARKET 9
1.4 CURRENCY AND PRICING 11
1.5 LIMITATIONS 11
1.6 MARKETS COVERED 11
2 MARKET SEGMENTATION 13
2.1 MARKETS COVERED 13
2.2 GEOGRAPHICAL SCOPE 14
2.3 YEARS CONSIDERED FOR THE STUDY 15
2.4 CURRENCY AND PRICING 15
2.5 DBMR TRIPOD DATA VALIDATION MODEL 16
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 19
2.7 DBMR MARKET POSITION GRID 20
2.8 DBMR VENDOR SHARE ANALYSIS 21
2.9 MULTIVARIATE MODELING 21
2.10 PRODUCTS LIFELINE CURVE 22
2.11 SECONDARY SOURCES 23
2.12 ASSUMPTIONS 23
3 MARKET OVERVIEW 24
3.1 DRIVERS 24
3.1.1 INCREASING PREVALENCE OF DRY EYE DISEASES 24
3.1.2 INCREASING AWARENESS ABOUT DIAGNOSIS AND TREATMENT OF THE DISEASE 24
3.1.3 RISING GERIATRIC POPULATION 25
3.1.4 USAGE OF CONTACT LENSES 25
3.2 RESTRAINTS 26
3.2.1 STRINGENT REGULATORY PROCESS 26
3.2.2 UNMET MEDICAL NEEDS 26
3.3 OPPORTUNITIES 27
3.3.1 DEVELOPMENT OF NOVEL TECHNOLOGIES 27
3.4 CHALLENGE 27
3.4.1 INCREASING NUMBER OF PLAYERS 27
4 EXECUTIVE SUMMARY 28
5 PREMIUM INSIGHTS 30
6 TURKEY RX DRY EYE MARKET, BY PRODUCT TYPE 31
6.1 OVERVIEW 32
6.2 LUBRICANT EYE DROPS/SOLUTIONS 33
6.2.1 OILY TEAR EYE DROP 33
6.2.2 PRESERVATIVE-FREE DROPS 33
6.3 EMULSIONS 33
6.4 EYE OINTMENTS 33
6.5 NUTRITION SUPPLEMENTS 34
6.6 AUTOLOGOUS SERUM EYE DROPS 34
6.7 OTHERS 34
7 TURKEY RX DRY EYE MARKET, BY DISEASE TYPE 35
7.1 OVERVIEW 36
7.2 EVAPORATIVE DRY EYE SYNDROME 37
7.3 AQUEOUS DRY EYE SYNDROME 37
8 TURKEY RX DRY EYE MARKET, BY TREATMENT TYPE 38
8.1 OVERVIEW 39
8.2 LUBRICATING AGENTS 40
8.3 TEAR STIMULATORS 40
8.4 ANTI-INFLAMMATORY DRUGS 40
8.5 ARTIFICIAL TEARS 40
8.6 ANTIBIOTIC DRUGS 40
8.7 OTHERS 40
9 TURKEY RX DRY EYE MARKET, BY END USER 41
9.1 OVERVIEW 42
9.2 HOME HEALTHCARE 43
9.3 HOSPITALS 43
9.4 CLINICS 43
9.5 OTHERS 43
10 TURKEY RX DRY EYE MARKET, BY DISTRIBUTION CHANNEL 44
10.1 OVERVIEW 45
10.2 RETAIL PHARMACIES 46
10.3 HOSPITAL PHARMACIES 46
10.4 ONLINE PHARMACIES 46
10.5 OTHERS 46
11 TURKEY RX DRY EYE MARKET, COMPANY LANDSCAPE 47
11.1 COMPANY SHARE ANALYSIS: TURKEY 47
12 COMPANY PROFILES 48
12.1 NOVARTIS AG 48
12.1.1 COMPANY SNAPSHOT 48
12.1.2 COMPANY SHARE ANALYSIS 48
12.1.3 REVENUE ANALYSIS 49
12.1.4 GEOGRAPHICAL PRESENCE 49
12.1.5 PRODUCT PORTFOLIO 50
12.1.6 RECENT DEVELOPMENT 50
12.2 BAUSCH & LOMB INCORPORATED. 51
12.2.1 COMPANY SNAPSHOT 51
12.2.2 COMPANY SHARE ANALYSIS 51
12.2.3 REVENUE ANALYSIS 52
12.2.4 GEOGRAPHICAL PRESENCE 52
12.2.5 PRODUCT PORTFOLIO 53
12.2.6 RECENT DEVELOPMENT 54
12.3 ALLERGAN 55
12.3.1 COMPANY SNAPSHOT 55
12.3.2 COMPANY SHARE ANALYSIS 55
12.3.3 REVENUE ANALYSIS 56
12.3.4 GEOGRAPHICAL PRESENCE 56
12.3.5 PRODUCT PORTFOLIO 57
12.3.6 RECENT DEVELOPMENTS 58
12.4 ALCON INC 59
12.4.1 COMPANY SNAPSHOT 59
12.4.2 COMPANY SHARE ANALYSIS 59
12.4.3 REVENUE ANALYSIS 60
12.4.4 GEOGRAPHICAL PRESENCE 60
12.4.5 PRODUCT PORTFOLIO 61
12.5 JOHNSON & JOHNSON SERVICES, INC. 62
12.5.1 COMPANY SNAPSHOT 62
12.5.2 COMPANY SHARE ANALYSIS 62
12.5.3 REVENUE ANALYSIS 63
12.5.4 GEOGRAPHICAL PRESENCE 63
12.5.5 PRODUCT PORTFOLIO 64
12.5.6 RECENT DEVELOPMENTS 65
?
12.6 TEVA PHARMACEUTICAL INDUSTRIES LTD. 66
12.6.1 COMPANY SNAPSHOT 66
12.6.2 REVENUE ANALYSIS 66
12.6.3 GEOGRAPHICAL PRESENCE 67
12.6.4 PRODUCT PORTFOLIO 67
12.6.5 RECENT DEVELOPMENT 67
13 QUESTIONNAIRE 68
14 RELATED REPORTS 71